Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › FL › Tampa › NPI 1891731626
Lab

Quest Diagnostics Clinical Laboratories INC

Quest Diagnostics Clinical Laboratories INC was paid $49.99M by Medicaid between Jan 2018 and Dec 2024, across 495 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 11% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
TAMPA, FL 33617
33aNPI1891731626assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$49.99M
24GClaims11,118,874
24DCodes billed495
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#4 of 225
Median peer was paid$74K
This provider vs. median680×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$500K$1.0M$1.5M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018754,691$1.44M
20192,130,778$6.98M
20201,445,123$7.14M
20211,630,838$8.74M
20221,872,981$10.27M
20231,942,655$9.41M
2024incomplete1,341,808$6.02M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 11% 84,020 72,598 $5.29M
80061 Lipid panel 6.6% 688,369 599,956 $3.32M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.8% 264,869 239,243 $2.88M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 4.3% 237,439 203,267 $2.15M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 3.8% 8,984 8,318 $1.89M
83036 Hemoglobin; glycosylated (A1C) 3.2% 449,228 388,064 $1.58M
86003 2.3% 35,229 28,897 $1.17M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.3% 263,593 238,035 $1.14M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 2.2% 71,881 65,713 $1.08M
87088 2.1% 170,501 145,525 $1.03M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.9% 69,686 63,572 $927K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.8% 9,222 8,435 $924K
483 more codes
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.8% 79,444 $917K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.8% 63,982 $897K
87086 Culture, bacterial; quantitative colony count, urine 1.7% 256,414 $872K
80053 Comprehensive metabolic panel 1.6% 874,646 $819K
80050 General health panel 1.6% 59,900 $799K
84443 Thyroid stimulating hormone (TSH) 1.4% 525,708 $717K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.3% 27,935 $674K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.3% 175,039 $673K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.3% 826,887 $660K
86480 1.3% 33,674 $640K
82728 1.2% 100,236 $587K
84439 1.2% 210,440 $586K
80074 1.1% 32,824 $574K
80055 1.0% 23,442 $502K
86803 1.0% 103,300 $500K
80081 <1% 22,128 $468K
87340 <1% 78,149 $440K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 19,889 $436K
82746 <1% 112,857 $436K
81513 <1% 11,914 $417K
36415 Collection of venous blood by venipuncture <1% 387,918 $412K
87536 <1% 50,219 $399K
81511 <1% 5,886 $368K
82105 <1% 30,885 $301K
84153 <1% 56,992 $288K
86235 <1% 25,819 $286K
83655 <1% 43,260 $273K
81443 <1% 511 $272K
88142 <1% 30,698 $266K
82670 <1% 18,808 $264K
83013 <1% 12,368 $234K
87081 <1% 53,594 $232K
82607 <1% 163,013 $231K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 3,035 $227K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 1,801 $204K
82785 <1% 28,060 $187K
87070 <1% 71,213 $187K
84403 <1% 38,884 $186K
86787 <1% 20,903 $183K
84702 <1% 37,547 $180K
84481 <1% 37,169 $178K
81001 <1% 345,762 $177K
87522 Neg quan hep c or qual rna <1% 15,801 $176K
87209 <1% 19,804 $173K
82627 <1% 10,392 $167K
84146 <1% 23,524 $162K
87186 <1% 82,986 $160K
82652 <1% 19,847 $156K
86038 <1% 40,873 $148K
86592 <1% 143,121 $141K
83970 <1% 34,126 $138K
84402 <1% 17,444 $138K
85660 <1% 20,319 $130K
87902 <1% 2,599 $125K
86800 <1% 17,781 $122K
86696 <1% 20,667 $117K
85652 <1% 74,876 $111K
82784 <1% 24,198 $111K
85027 <1% 126,448 $110K
87799 <1% 36,852 $104K
83001 <1% 27,844 $101K
87449 <1% 10,080 $82K
83020 <1% 16,083 $82K
86160 <1% 17,296 $81K
88141 <1% 13,340 $81K
82570 <1% 166,516 $78K
87901 <1% 2,955 $76K
82150 <1% 12,455 $76K
87338 <1% 12,462 $74K
88342 <1% 3,881 $71K
86360 <1% 38,402 $70K
82550 <1% 22,096 $70K
83735 <1% 49,635 $66K
84480 <1% 30,047 $64K
82951 <1% 11,286 $63K
80349 <1% 4,260 $61K
84479 <1% 38,279 $60K
87481 <1% 5,191 $59K
86665 <1% 5,309 $59K
82950 <1% 47,983 $58K
82465 <1% 10,671 $58K
81243 <1% 4,599 $58K
86695 <1% 20,669 $57K
87480 <1% 6,879 $56K
86762 <1% 15,126 $53K
80048 Basic metabolic panel (calcium, ionized) <1% 65,232 $53K
86317 <1% 12,698 $53K
81329 <1% 3,677 $52K
86364 <1% 5,907 $52K
85730 <1% 29,288 $52K
82677 <1% 6,142 $52K
83021 <1% 11,036 $51K
84445 <1% 3,097 $51K
84436 <1% 66,624 $50K
83550 <1% 91,733 $50K
86300 <1% 7,064 $49K
83540 <1% 104,937 $48K
82274 <1% 20,899 $48K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 2,088 $46K
86706 <1% 26,121 $45K
86769 <1% 9,143 $44K
82378 <1% 10,532 $44K
84144 <1% 11,226 $44K
84681 <1% 8,421 $43K
83525 <1% 24,393 $43K
83615 <1% 14,610 $43K
83002 <1% 24,618 $43K
86021 <1% 3,859 $43K
83993 <1% 5,866 $42K
86850 <1% 14,400 $42K
83880 <1% 9,486 $41K
82977 <1% 11,378 $40K
86704 <1% 27,175 $39K
83921 <1% 3,916 $39K
87077 <1% 76,780 $39K
86140 <1% 67,853 $38K
81229 <1% 926 $38K
82043 <1% 135,463 $38K
86304 <1% 4,613 $37K
87660 <1% 6,832 $36K
87631 <1% 1,821 $36K
82947 <1% 13,907 $35K
82533 <1% 8,051 $34K
82672 <1% 4,480 $34K
86780 <1% 12,305 $34K
86146 <1% 4,990 $34K
80348 <1% 1,584 $33K
80164 <1% 13,783 $33K
86336 <1% 6,151 $32K
86708 <1% 23,181 $32K
82103 <1% 2,084 $32K
84305 <1% 5,695 $32K
86008 <1% 5,601 $31K
86481 <1% 692 $31K
87512 <1% 14,872 $31K
86376 <1% 26,880 $31K
83520 <1% 17,732 $31K
82085 <1% 2,346 $30K
86334 <1% 8,232 $30K
83521 <1% 3,469 $29K
87900 <1% 2,954 $29K
80197 <1% 18,709 $29K
86225 <1% 10,824 $28K
83090 <1% 8,076 $28K
88112 <1% 5,500 $28K
87205 <1% 15,465 $27K
87497 <1% 4,206 $27K
83516 <1% 15,487 $27K
87075 <1% 11,901 $26K
86147 <1% 7,761 $26K
86644 <1% 1,764 $25K
84154 <1% 8,718 $25K
84550 <1% 55,130 $25K
80323 <1% 1,457 $25K
82024 <1% 2,993 $24K
80361 <1% 3,837 $24K
80076 <1% 21,068 $23K
80373 <1% 1,930 $23K
87625 <1% 2,078 $22K
87150 <1% 3,026 $21K
88230 <1% 392 $21K
81512 <1% 850 $21K
85247 <1% 389 $20K
87517 <1% 2,842 $20K
87563 <1% 3,400 $20K
86765 <1% 6,250 $20K
86200 <1% 12,575 $20K
86361 <1% 13,273 $19K
87506 <1% 299 $19K
81025 <1% 1,899 $19K
86341 <1% 1,590 $19K
87046 <1% 6,374 $19K
84207 <1% 2,495 $18K
82157 <1% 750 $18K
86777 <1% 2,607 $18K
86255 <1% 8,257 $17K
84466 <1% 4,286 $17K
82626 <1% 506 $17K
87510 <1% 6,834 $16K
83690 <1% 15,779 $16K
85610 <1% 53,920 $16K
83498 <1% 3,259 $16K
86735 <1% 5,821 $16K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 655 $15K
87177 <1% 19,718 $15K
86682 <1% 2,107 $15K
88304 <1% 1,843 $15K
85246 <1% 1,216 $15K
86301 <1% 2,469 $15K
84156 <1% 44,282 $15K
84270 <1% 7,838 $15K
82653 <1% 1,017 $14K
81596 <1% 2,124 $14K
82542 <1% 2,503 $14K
81241 <1% 730 $14K
82330 <1% 4,214 $14K
84482 <1% 1,442 $14K
86709 <1% 3,374 $14K
80069 <1% 22,251 $13K
80346 <1% 2,342 $13K
87906 <1% 559 $13K
82247 <1% 10,654 $13K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 22,750 $13K
81003 <1% 51,805 $13K
87255 <1% 939 $12K
80354 <1% 1,428 $12K
85240 <1% 1,384 $12K
82140 <1% 5,822 $12K
88312 <1% 503 $12K
87529 <1% 532 $12K
82657 <1% 1,524 $11K
86431 <1% 25,223 $11K
85045 <1% 13,166 $11K
82668 <1% 2,077 $11K
80320 <1% 1,534 $11K
83718 <1% 4,439 $11K
80365 <1% 4,248 $11K
82390 <1% 2,280 $11K
87147 <1% 25,945 $10K
80178 <1% 4,624 $10K
86870 <1% 2,249 $10K
82248 <1% 31,880 $10K
80156 <1% 3,027 $10K
80177 <1% 7,207 $10K
80321 <1% 941 $10K
86335 <1% 2,023 $10K
83519 <1% 2,353 $10K
85018 <1% 17,653 $9K
86900 <1% 13,382 $9K
84703 <1% 7,708 $9K
83010 <1% 2,184 $9K
88341 <1% 983 $9K
86705 <1% 3,838 $9K
82088 <1% 1,108 $9K
84425 <1% 4,287 $8K
87329 <1% 7,247 $8K
88313 <1% 146 $8K
86162 <1% 2,774 $8K
82787 <1% 1,135 $8K
82040 <1% 8,068 $8K
86039 <1% 10,640 $8K
81257 <1% 96 $7K
87427 <1% 11,307 $7K
84165 <1% 11,908 $7K
85379 <1% 2,440 $7K
82952 <1% 9,367 $7K
87045 <1% 12,179 $7K
85014 <1% 15,066 $7K
86812 <1% 1,045 $6K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 7,067 $6K
86258 <1% 481 $6K
82565 <1% 14,691 $6K
86141 <1% 6,478 $6K
80202 <1% 3,109 $6K
80324 <1% 902 $6K
84100 <1% 27,151 $6K
87040 <1% 1,928 $6K
82310 <1% 9,234 $6K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 201 $6K
84460 <1% 13,551 $6K
83014 <1% 4,808 $5K
87102 <1% 1,774 $5K
86381 <1% 1,206 $5K
84134 <1% 1,873 $5K
80175 <1% 3,511 $5K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 5,711 $5K
86645 <1% 1,414 $5K
87101 <1% 1,519 $5K
82139 <1% 313 $5K
84520 <1% 9,626 $5K
85300 <1% 464 $5K
84432 <1% 2,317 $5K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 563 $5K
85306 <1% 694 $5K
86901 <1% 13,563 $5K
85060 <1% 966 $5K
85613 <1% 2,911 $4K
80358 <1% 2,090 $4K
83835 <1% 448 $4K
83003 <1% 348 $4K
84450 <1% 12,737 $4K
86060 <1% 449 $4K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 974 $4K
82232 <1% 1,257 $4K
86359 <1% 8,670 $4K
86664 <1% 3,599 $4K
87493 <1% 970 $4K
80185 <1% 2,645 $4K
84182 <1% 80 $4K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 12,455 $3K
82104 <1% 447 $3K
80353 <1% 981 $3K
86015 <1% 1,362 $3K
86593 <1% 7,787 $3K
82172 <1% 2,724 $3K
87535 <1% 97 $3K
80299 <1% 1,186 $3K
82610 <1% 452 $3K
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 2,628 $3K
84075 <1% 7,048 $3K
86778 <1% 1,207 $3K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 17,113 $3K
85245 <1% 1,077 $3K
84155 <1% 12,175 $3K
86618 <1% 1,384 $3K
80165 <1% 1,383 $3K
87324 <1% 4,735 $3K
80051 <1% 2,741 $3K
82397 <1% 1,612 $3K
84166 <1% 2,526 $3K
80345 <1% 1,572 $3K
80183 <1% 1,430 $3K
86702 <1% 1,792 $3K
80159 <1% 1,262 $2K
89055 <1% 1,635 $2K
84630 <1% 3,087 $2K
83721 <1% 5,570 $2K
85041 <1% 6,562 $2K
80184 <1% 1,096 $2K
86880 <1% 1,241 $2K
86308 <1% 499 $2K
83704 <1% 1,316 $2K
82747 <1% 996 $2K
82530 <1% 419 $2K
80356 <1% 799 $2K
80377 <1% 1,086 $2K
84590 <1% 1,201 $2K
83883 <1% 2,476 $2K
82575 <1% 637 $2K
84478 <1% 3,958 $2K
82164 <1% 1,559 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 93 $2K
80162 <1% 722 $2K
83992 <1% 1,245 $2K
83695 <1% 2,394 $2K
80362 <1% 717 $2K
84244 <1% 1,013 $2K
82525 <1% 1,443 $2K
86774 <1% 914 $1K
80370 <1% 1,104 $1K
80368 <1% 1,128 $1K
86337 <1% 234 $1K
80337 <1% 1,272 $1K
85303 <1% 684 $1K
80338 <1% 1,288 $1K
85004 <1% 1,214 $1K
82985 <1% 1,936 $1K
80235 <1% 299 $1K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 1,722 $1K
86701 <1% 1,811 $1K
81240 <1% 302 $1K
84132 <1% 1,793 $1K
87662 <1% 102 $1K
86794 <1% 173 $1K
80363 <1% 875 $1K
82705 <1% 521 $1K
80326 <1% 1,271 $1K
87350 <1% 512 $1K
86355 <1% 1,787 $1K
85049 <1% 1,259 $1K
80332 <1% 853 $1K
87425 <1% 146 $1K
81015 <1% 3,992 $1K
86231 <1% 162 $1K
85384 <1% 329 $1K
87076 <1% 2,195 $1K
80339 <1% 1,060 $1K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,067 $1K
86357 <1% 1,245 $1K
80342 <1% 852 $1K
82166 <1% 107 $1K
81381 <1% 76 $937.15
80158 <1% 526 $903.15
80329 <1% 1,072 $879.64
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 528 $870.24
86036 <1% 900 $868.34
85598 <1% 158 $838.71
82955 <1% 563 $830.43
87206 <1% 2,328 $780.73
84080 <1% 243 $772.28
85048 <1% 2,044 $755.72
87650 <1% 151 $743.43
87807 <1% 160 $735.95
82340 <1% 368 $719.75
87106 <1% 540 $713.88
86648 <1% 660 $704.95
81206 <1% 47 $671.54
84484 <1% 252 $630.10
86340 <1% 134 $556.58
80372 <1% 184 $541.49
85007 <1% 3,858 $515.51
84295 <1% 2,370 $506.49
83698 <1% 640 $484.77
87185 <1% 1,011 $474.97
86671 <1% 537 $461.54
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 2,935 $411.04
82435 <1% 2,168 $410.30
86886 <1% 639 $407.48
83605 <1% 143 $388.97
84300 <1% 1,575 $361.29
82374 <1% 1,818 $360.49
84140 <1% 202 $356.22
86148 <1% 208 $351.05
86738 <1% 77 $346.79
86617 <1% 327 $332.63
86382 <1% 13 $322.88
80201 <1% 177 $316.62
84446 <1% 489 $309.64
83935 <1% 316 $306.98
80357 <1% 159 $302.31
80195 <1% 270 $294.49
81291 <1% 89 $276.64
87328 <1% 137 $274.22
80355 <1% 235 $270.90
86316 <1% 54 $256.58
80369 <1% 368 $251.15
80360 <1% 75 $233.75
86747 <1% 141 $230.40
82523 <1% 34 $213.85
84376 <1% 235 $197.69
83789 <1% 14 $187.18
87521 Neg quan hep c or qual rna <1% 129 $186.30
82175 <1% 12 $176.14
83986 <1% 137 $161.91
87220 <1% 793 $157.48
84145 <1% 17 $154.93
86001 <1% 160 $152.70
84210 <1% 56 $148.31
G0475 Hiv antigen/antibody, combination assay, screening <1% 774 $148.19
86707 <1% 241 $139.43
80359 <1% 71 $136.26
80330 <1% 139 $134.62
87116 <1% 83 $132.62
84133 <1% 391 $120.13
87467 <1% 14 $118.38
84378 <1% 491 $117.54
82379 <1% 233 $116.37
88164 <1% 14 $107.35
83930 <1% 149 $104.09
80364 <1% 41 $99.87
80333 <1% 43 $96.87
80367 <1% 30 $95.31
83625 <1% 15 $90.24
80340 <1% 43 $82.97
80344 <1% 43 $77.38
82656 <1% 234 $76.08
87015 <1% 250 $73.63
87272 <1% 174 $60.19
86684 <1% 30 $59.76
83630 <1% 15 $52.76
82608 <1% 90 $51.09
80366 <1% 31 $33.19
86905 <1% 211 $25.17
82436 <1% 54 $24.88
83527 <1% 35 $21.24
84255 <1% 16 $19.32
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 81 $18.88
85302 <1% 26 $17.02
85597 <1% 27 $15.36
86161 <1% 15 $15.13
87107 <1% 126 $14.63
83825 <1% 16 $13.57
86611 <1% 37 $12.98
82239 <1% 15 $12.48
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 890 $12.44
87254 <1% 14 $10.62
86663 <1% 15 $10.62
86256 <1% 96 $8.38
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 1,227 $5.90
82384 <1% 15 $5.90
82679 <1% 13 $5.90
86343 <1% 13 $5.90
85385 <1% 13 $5.47
83631 <1% 29 $4.72
87140 <1% 33 $4.46
84560 <1% 41 $3.65
84252 <1% 27 $3.33
82017 <1% 40 $2.36
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 193 $2.07
88262 0% 385 $0.00
83918 0% 95 $0.00
87184 0% 30 $0.00
85305 0% 15 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.